ReviewCancers2021
ALT Positivity in Human Cancers: Prevalence and Clinical Insights.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs role in telomere length maintenance and telomerase activity in tumor cells.Journal of molecular medicine (Berlin, Germany) · 2024Pooled it
- Paediatric therapeutic development workshop on osteosarcoma.British journal of cancer · 2026Review
- SMARCAL1 is a candidate therapeutic target for ALT-positive tumors.Genes & development · 2026Article
- Detection of Longer Leukocyte Telomere Length in Patients With Bone Sarcomas.World journal of oncology · 2026Article
- Telomeric DNA-Promyelocytic Leukemia (TEL-PML) Colocalization as an ALT Proxy in Relation to Metastatic Behavior in Osteosarcoma: A Retrospective Cohort Study.Current issues in molecular biology · 2026Article
- Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
- DAXX and ATRX Expression in Canine Prostate and Bladder Cancer Identified by Immunohistochemistry-A Digital Quantitative Pilot Study.Veterinary sciences · 2025Article
- Decoding osteosarcoma from heterogeneity to precision therapy.Discover oncology · 2025Review
- The alternative lengthening of telomeres pathway through a DNA repair lens: mechanism and therapeutic opportunities.NAR cancer · 2025Review
- Emerging hallmarks and the rise of complexities and heterogeneity of tumor.Biochemistry and biophysics reports · 2025Review
- Review
- Silencing of SOD1 sensitises ATRX-deficient cells to camptothecin treatment through increased activity of the alternative lengthening of telomeres pathway.Human molecular genetics · 2025Article
- Optical pooled screening for the discovery of regulators of the alternative lengthening of telomeres pathway.Methods (San Diego, Calif.) · 2025Article
- Atypical R-loops in cancer: decoding molecular chaos for therapeutic gain.Journal of translational medicine · 2025Review
- Alternative Lengthening of Telomeres: The Need forInternational journal of molecular sciences · 2025Article
- Prediction of lung adenocarcinoma prognosis and clinical treatment efficacy by telomere-associated gene risk model.Discover oncology · 2025Article
- Targeting FANCM using the antisense oligonucleotides to treat the ALT-positive cancers.Molecular therapy. Nucleic acids · 2025Article
- Telomere Maintenance Pathways in Lower-Grade Gliomas: Insights from Genetic Subtypes and Telomere Length Dynamics.International journal of molecular sciences · 2025Article
- Interactions between long non-coding RNAs and m6 A modification in cancer.Discover oncology · 2025Review
- Multiple functions of the ALT favorite helicase, BLM.Cell & bioscience · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many exciting advances in cancer-related telomere biology have been made in the past decade. Of these recent advances, great progress has also been made with respect to the Alternative Lengthening of Telomeres (ALT) pathway. Along with a better understanding of the molecular mechanism of this unique telomere maintenance pathway, many studies have also evaluated ALT activity in various cancer subtypes. We first briefly review and assess a variety of commonly used ALT biomarkers. Then, we provide both an update on ALT-positive (ALT+) tumor prevalence as well as a systematic clinical assessment of the presently studied ALT+ malignancies. Additionally, we discuss the pathogenetic alterations in ALT+ cancers, for example, the mutation status of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.